BC
AXSM icon

Bayforest Capital’s Axsome Therapeutics AXSM Stock Holding History

Bayforest Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$163K Buy
963
+485
+101% +$83.8K 0.18% 188
2025
Q4 		$87.3K Sell
478
-584
-55% -$81.5K 0.07% 500
2025
Q3 		$129K Buy
+1,062
New +$120K 0.06% 473

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bayforest Capital's AXSM Position: Q1 2026 in Review

Bayforest Capital increased its Axsome Therapeutics (AXSM) stake by 101% in Q1 2026, buying an estimated $83.8K and bringing the position to 963 shares worth $163K. The position accounts for 0.18% of the portfolio, ranked #188.

Bayforest Capital first reported a position in AXSM in Q3 2025 and has held it in 3 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Bayforest Capital held 963 shares of Axsome Therapeutics worth $163K as of Q1 2026.
  • Bayforest Capital bought 485 Axsome Therapeutics shares in Q1 2026, an estimated $83.8K.
  • Axsome Therapeutics made up 0.18% of Bayforest Capital's portfolio in Q1 2026, its #188 holding.
  • Bayforest Capital first reported a position in Axsome Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Bayforest Capital's 13F filing for Q1 2026, filed 15 Apr 2026.